Therapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesothelioma

$313,142R01FY2020CANIH

Columbia University Health Sciences, New York NY

Investigators

Filippo G Giancotticontact

Linked publications, trials & patents

Paper 34224367 Paper 30889378 Paper 30038252 Paper 28468780 Paper 28244491

View original record on NIH RePORTER →